SCHEMBL10148314

SCHEMBL10148314

CCOC(=O)CC1CCN(c2cc(F)c(C(C)=O)cc2F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
MAPT P10636 4/20 0.55
HTT P42858 4/20 0.55
TSHR P16473 2/20 0.48
LMNA P02545 3/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GPR174 Q9BXC1 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
ITGB3 P05106 3/20 0.41
ITGA2B P08514 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10148313 0.91 MAPT (0.46) ALDH1A1MAPTHTTTSHRLMNA
SCHEMBL10148332 0.83 L3MBTL1 (0.66) ALDH1A1MAPTTSHRLMNAMAPK1
SCHEMBL19510704 0.81 L3MBTL1 (0.46) ALDH1A1MAPTHTTTSHRLMNA
SCHEMBL30350660 0.81 L3MBTL1 (0.46) ALDH1A1MAPTHTTTSHRLMNA
SCHEMBL10148316 0.79 FFAR4 (0.48) MAPTL3MBTL1FFAR4ITGB3ITGA2B
SCHEMBL10148330 0.78 L3MBTL1 (0.54) ALDH1A1MAPTTSHRLMNAMAPK1
SCHEMBL25035144 0.77 L3MBTL1 (0.45) ALDH1A1MAPTTSHRLMNAMAPK1
SCHEMBL31334246 0.76 MAPT (0.61) ALDH1A1MAPTHTTLMNAMAPK1
SCHEMBL19511081 0.75 FFAR4 (0.48) FFAR4
SCHEMBL19511268 0.75 FFAR4 (0.48) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 ALDH1A1 963/4885MAPT 2628/4885HTT 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.